---
layout: default
title: Sugammadex
parent: 僅模型預測 (L5)
nav_order: 928
evidence_level: L5
indication_count: 10
---

# Sugammadex
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Sugammadex: From Neuromuscular Blockade Reversal to Breast Fibrocystic Disease

## One-Sentence Summary

> Sugammadex is a modified γ-cyclodextrin used clinically to reverse rocuronium/vecuronium-induced neuromuscular blockade during general anaesthesia.
> The TxGNN model flags a possible association with **Breast Fibrocystic Disease**, but this is one of the model's lowest-confidence output categories,
> currently supported by **0 clinical trials** and **0 publications**, and the model's own generated rationale finds no plausible mechanistic link.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Reversal of steroidal neuromuscular blocking agents (rocuronium/vecuronium) — inferred from evidence text; no formal Singapore label text available |
| Predicted New Indication | Breast Fibrocystic Disease |
| TxGNN Prediction Score | 98.49% |
| Evidence Level | L5 |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for sugammadex is not available in DrugBank for this pack (DG002, High severity gap). However, evidence text collected across other candidate indications consistently describes sugammadex's known pharmacology: it is a modified γ-cyclodextrin that physically encapsulates and chelates steroidal neuromuscular blocking agents (rocuronium, vecuronium), inactivating them rather than acting on a receptor or enzyme system.

Breast fibrocystic disease is a hormonally-driven epithelial/stromal proliferative condition of the breast. There is no established pharmacological pathway connecting cyclodextrin-mediated drug encapsulation to hormonal or epithelial proliferation biology. The evidence pack's own repurposing rationale for this candidate states explicitly that the high TxGNN score reflects knowledge-graph embedding similarity rather than any mechanistic or clinical signal.

**Conclusion of this assessment**: the prediction is not currently mechanistically reasonable. It should be treated as a model-generated hypothesis requiring independent biological rationale before further investment, not as a validated repurposing signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Singapore Market Information

Sugammadex currently has no product registrations in Singapore (0 licenses on file); the drug is classified as **Not Marketed** in this jurisdiction.

---

## Safety Considerations

Please refer to the package insert for safety information. Note: HSA-equivalent label warnings/contraindications and DrugBank DDI data have not yet been retrieved for this drug (DG001, Blocking severity) — this gap must be closed before any safety-related decision (S1 stage) can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate has Evidence Level L5 (model prediction only — no clinical trials, no literature, no case reports of any kind for this specific indication), and the mechanistic rationale generated alongside the prediction explicitly finds no biological link between sugammadex's cyclodextrin-encapsulation mechanism and breast fibrocystic disease pathology. There is no basis to advance this candidate past initial screening.

**To proceed, the following is needed:**
- Close DG001 (HSA/TFDA-equivalent label warnings and contraindications) — currently a Blocking gap preventing any S1 safety evaluation
- Close DG002 (confirmed DrugBank mechanism-of-action record) to formally document sugammadex's pharmacology
- Independent literature or preclinical search specifically targeting sugammadex and breast/fibrocystic tissue biology, since none currently exists
- If no mechanistic or clinical rationale emerges, deprioritize this candidate in favor of higher-evidence predictions in the same pack (e.g., rank 6 "thrombotic disease" and rank 10 "female breast carcinoma," which at least have L4-tier literature, though still requiring safety-focused rather than efficacy-focused interpretation)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

